-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
On March 23, the CDE official website showed that Sichuan Kelun Botai’s new class 1 drug KL130008 capsule was approved for clinical use (acceptance number: CXHL2101850/1/2), and clinical trials will be carried out for severe alopecia areata
Source: CDE official website
KL130008 Capsule is an innovative small molecule JAK inhibitor independently developed by Kelun Pharmaceutical with intellectual property rights, and is intended for the treatment of rheumatoid arthritis
According to the Insight database, KL130008 was first approved for clinical use in June 2018 for the treatment of rheumatoid arthritis, and phase II clinical trials have been started
KL13008 Project Details (Insight)
From: Insight database project progress module (http://db.
Kelun Pharmaceutical's innovative drugs mainly come from its subsidiary Kelun Botai
Columbotai Product Overview
From: Insight Database Enterprise Analysis Module (http://db.